{"database": "openregs", "table": "dockets", "rows": [["FDA-2026-P-4800", "FDA", "Requests that the FDA declare that the proposed drug product, Apixaban orally di sintegrating tablets 2.5 mg and 5 mg is suitable for submission as an ANDA. The listed reference drug product (RLD), upon which this petition is based, is ELIQUIS\u00ae (apixaban) Tablets, 2.5 mg and 5 mg, by Bristol-Myers Squibb, NDA #202155", "Nonrulemaking", "2026-05-04T17:21:12Z", "0b000064b92c100b"]], "columns": ["id", "agency_id", "title", "docket_type", "last_modified", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2026-P-4800"], "units": {}, "query_ms": 0.492213002871722, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}